世界中医药
世界中醫藥
세계중의약
WORLD CHINESE MEDICINE
2013年
12期
1442-1444
,共3页
脑心通胶囊%急性冠脉综合症%疗效%血脂%超敏C反应蛋白
腦心通膠囊%急性冠脈綜閤癥%療效%血脂%超敏C反應蛋白
뇌심통효낭%급성관맥종합증%료효%혈지%초민C반응단백
Effect of Naoxintong capsule%Acute coronary syndrome%Curative effect%Blood lipids%High-sensitivity c-reactive protein
目的：观察步长脑心通胶囊对急性冠脉综合征（ACS）血脂水平及超敏C反应蛋白（hs-CRP）的影响。方法：将120例ACS患者按数字表法随机分为对照组和观察组各60例，对照组给予常规治疗，观察组在对照组基础上联合步长脑心通胶囊治疗，观察1个治疗周期后两组主要不良心血管事件（MACE）及血脂、hs-CRP血清水平变化情况。结果：观察组MACE发生率5.00％明显低于对照组18.33％，差异有统计学意义（ P＜0.05）；观察组血脂及hs-CRP均较对照组改善更为明显，差异均有统计学意义（ P＜0.05）；两组不良反应发生率差异无统计学意义（ P＞0.05）。结论：步长脑心通胶囊可安全、强效纠正ACS患者血脂异常，抑制炎症反应，显著降低MACE发生，检验科为临床诊治ACS的疗效观察提供及时有效的保障。
目的：觀察步長腦心通膠囊對急性冠脈綜閤徵（ACS）血脂水平及超敏C反應蛋白（hs-CRP）的影響。方法：將120例ACS患者按數字錶法隨機分為對照組和觀察組各60例，對照組給予常規治療，觀察組在對照組基礎上聯閤步長腦心通膠囊治療，觀察1箇治療週期後兩組主要不良心血管事件（MACE）及血脂、hs-CRP血清水平變化情況。結果：觀察組MACE髮生率5.00％明顯低于對照組18.33％，差異有統計學意義（ P＜0.05）；觀察組血脂及hs-CRP均較對照組改善更為明顯，差異均有統計學意義（ P＜0.05）；兩組不良反應髮生率差異無統計學意義（ P＞0.05）。結論：步長腦心通膠囊可安全、彊效糾正ACS患者血脂異常，抑製炎癥反應，顯著降低MACE髮生，檢驗科為臨床診治ACS的療效觀察提供及時有效的保障。
목적：관찰보장뇌심통효낭대급성관맥종합정（ACS）혈지수평급초민C반응단백（hs-CRP）적영향。방법：장120례ACS환자안수자표법수궤분위대조조화관찰조각60례，대조조급여상규치료，관찰조재대조조기출상연합보장뇌심통효낭치료，관찰1개치료주기후량조주요불양심혈관사건（MACE）급혈지、hs-CRP혈청수평변화정황。결과：관찰조MACE발생솔5.00％명현저우대조조18.33％，차이유통계학의의（ P＜0.05）；관찰조혈지급hs-CRP균교대조조개선경위명현，차이균유통계학의의（ P＜0.05）；량조불량반응발생솔차이무통계학의의（ P＞0.05）。결론：보장뇌심통효낭가안전、강효규정ACS환자혈지이상，억제염증반응，현저강저MACE발생，검험과위림상진치ACS적료효관찰제공급시유효적보장。
Objective:To observe Buchang Naoxintong capsule in patients with acute coronary syndrome ( ACS ) lipids and effects on high sensitivity c-reactive protein ( HS-CRP) .Methods:One hundred and twenty patients with ACS were randomly assigned to a control group (n=60) observation group (n=60) according to digital meter method.The control group gave patients conventional treatment , and patients in the observation group gave patients extra Buchang Naoxintong .The major adverse cardiovascular events ( MACE) and changes in blood lipids ,serum hs-CRP levels of the two groups were observed after one treatment period .Results:The occurrence rate of MACE in the observation group was 5%,which was significantly lower than 18.33%of the control group (P<0.05);the improvements in lipid and hs-CRP are more obvious than those of the control group ,showing statistically significant difference (P<0.05); there was statistically significant difference between the two groups in the incidence of adverse reactions (P>0.05).Conclusion:Buchang Naox-intong capsule works safely to relieve dyslipidemia in patients with ACS ,and it can inhibit inflammation and significantly reduce occur-rence of MACE .It provides timely and effective protection for clinical observation of ACS .
